These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 18280028)

  • 1. Strategic paths for biomarker qualification.
    Goodsaid FM; Frueh FW; Mattes W
    Toxicology; 2008 Mar; 245(3):219-23. PubMed ID: 18280028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarker qualification pilot process at the US Food and Drug Administration.
    Goodsaid F; Frueh F
    AAPS J; 2007 Mar; 9(1):E105-8. PubMed ID: 17408233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cost-effectiveness approach to the qualification and acceptance of biomarkers.
    Williams SA; Slavin DE; Wagner JA; Webster CJ
    Nat Rev Drug Discov; 2006 Nov; 5(11):897-902. PubMed ID: 17080026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges of biomarkers in drug discovery and development.
    Goodsaid F
    Expert Opin Drug Discov; 2012 Jun; 7(6):457-61. PubMed ID: 22471322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Questions and answers about the Pilot Process for Biomarker Qualification at the FDA.
    Goodsaid FM; Frueh FW
    Drug Discov Today Technol; 2007; 4(1):9-11. PubMed ID: 24980714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel biomarkers of acute kidney toxicity.
    Goodsaid FM; Blank M; Dieterle F; Harlow P; Hausner E; Sistare F; Thompson A; Vonderscher J
    Clin Pharmacol Ther; 2009 Nov; 86(5):490-6. PubMed ID: 19710639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs.
    Wagner JA; Williams SA; Webster CJ
    Clin Pharmacol Ther; 2007 Jan; 81(1):104-7. PubMed ID: 17186007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prototypical process for creating evidentiary standards for biomarkers and diagnostics.
    Altar CA; Amakye D; Bounos D; Bloom J; Clack G; Dean R; Devanarayan V; Fu D; Furlong S; Hinman L; Girman C; Lathia C; Lesko L; Madani S; Mayne J; Meyer J; Raunig D; Sager P; Williams SA; Wong P; Zerba K
    Clin Pharmacol Ther; 2008 Feb; 83(2):368-71. PubMed ID: 18091762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Translational medicine and the value of biomarker qualification.
    Goodsaid FM; Mendrick DL
    Sci Transl Med; 2010 Sep; 2(47):47ps44. PubMed ID: 20811041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recommendations for the evaluation of pathology data in nonclinical safety biomarker qualification studies.
    Burkhardt JE; Pandher K; Solter PF; Troth SP; Boyce RW; Zabka TS; Ennulat D
    Toxicol Pathol; 2011 Dec; 39(7):1129-37. PubMed ID: 22116771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarkers in aquatic plants: selection and utility.
    Brain RA; Cedergreen N
    Rev Environ Contam Toxicol; 2009; 198():49-109. PubMed ID: 19253039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The European Medicines Agency experience with biomarker qualification.
    Manolis E; Koch A; Deforce D; Vamvakas S
    Methods Mol Biol; 2015; 1243():255-72. PubMed ID: 25384751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value, qualification, and regulatory use of surrogate end points in drug development.
    Lathia CD; Amakye D; Dai W; Girman C; Madani S; Mayne J; MacCarthy P; Pertel P; Seman L; Stoch A; Tarantino P; Webster C; Williams S; Wagner JA
    Clin Pharmacol Ther; 2009 Jul; 86(1):32-43. PubMed ID: 19474783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarkers and environmental risk assessment: guiding principles from the human health field.
    Owen R; Galloway TS; Hagger JA; Jones MB; Depledge MH
    Mar Pollut Bull; 2008 Apr; 56(4):613-9. PubMed ID: 18313083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating correlation-based metric for surrogate marker qualification within a causal correlation framework.
    Wang Y; Mogg R; Lunceford J
    Biometrics; 2012 Jun; 68(2):617-27. PubMed ID: 22059475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topic of histopathology blinding in nonclinical safety biomarker qualification studies.
    Burkhardt JE; Ennulat D; Pandher K; Solter PF; Troth SP; Boyce RW; Zabka TS
    Toxicol Pathol; 2010 Jun; 38(4):666-7. PubMed ID: 20530250
    [No Abstract]   [Full Text] [Related]  

  • 17. Biomarker discovery: validation and decision-making in product development.
    Niedbala RS; Mauck C; Harrison P; Doncel GF
    Sex Transm Dis; 2009 Mar; 36(3 Suppl):S76-80. PubMed ID: 19218888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proposal for levels of evidence schema for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and recommendations for study design.
    Maksymowych WP; Fitzgerald O; Wells GA; Gladman DD; Landewé R; Ostergaard M; Taylor WJ; Christensen R; Tak PP; Boers M; Syversen SW; Bathon JM; Ritchlin CJ; Mease PJ; Bykerk VP; Garnero P; Geusens P; El-Gabalawy H; Aletaha D; Inman RD; Kraus VB; Kvien TK; van der Heijde D
    J Rheumatol; 2009 Aug; 36(8):1792-9. PubMed ID: 19671814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in atherosclerosis-based proteomics: new biomarkers and a future perspective.
    Alvarez-Llamas G; de la Cuesta F; Barderas ME; Darde V; Padial LR; Vivanco F
    Expert Rev Proteomics; 2008 Oct; 5(5):679-91. PubMed ID: 18937558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification, validation and qualification of biomarkers for osteoarthritis in humans and companion animals: mission for the next decade.
    Mobasheri A; Henrotin Y
    Vet J; 2010 Aug; 185(2):95-7. PubMed ID: 20554463
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.